Research & Trials

Clinical trials in both imaging and therapy is an important focus of the St Vincent’s Theranostics department. We published the world first prospective trial demonstrating the superiority of GaPSMA-11 PET CT in men with prostate cancer in 2015, with multiple publications since. Similarly we have undertaken multiple prospective trials in theranostics therapies in the last few years. We also published the first prospective trial that combined Lu PSMA with a radiation sensitiser in 2020.

The department works closely with the oncology unit at the Kinghorn Cancer Centre, the prostate cancer research centre, the Garvan institute of medical research, St Vincent’s Clinic and St Vincent’s Private Hospital to achieve high quality, meaningful research and optimal patient journeys.

We are now working with multiple biotech companies to provide avenues to fast-track new theranostics discoveries into the clinic with phase 1 clinical trials. It is a truly exciting time in Theranostics – so watch this space!!
Multiple trials are currently open and enrolling in the department. Please check the list below and contact our staff if you have any queries on 83821830

Imaging trials in accrual or due to start 2021

Trial Name

Trial type

Agent

Cancer Type

Status

PI

PRIMARY trial

Prospective

Ga PSMA -11

MRI

Prostate (diagnosis)

Open Jan 2021

Prof Emmett

PRIMARY 2 trial

Prospective randomised

Ga PSMA -11

MRI

Prostate (diagnosis)

Opening 2021

Prof Emmett

Detect trial

Prospective

Tc PSMA 11

Prostate (pre-RP)

Open Jan 2021

Prof Phil Stricker

BOBCAT trial


Cu64 Bombesin

Breast (ER/PR+)

Open Jan 2021

Prof Emmett

Prof Lim

BOBCAT trial


Cu 64 Bombesin

Prostate (PSMA negative)

Open 2021

Prof Emmett

CAA



Brain tumours


Prof Emmett

Novartis trial

PIAS trial

Prospective

Ga PSMA 11

Prostate active surveillance study

Open Q1 2021

Dr James Thompson

Therapy trials in accrual or due to start 2021

Trial Name

Cancer Type

Status

Principal investigator

ENZA-p trial: Ph2 enzalutamide vs enzalutamide + LuPSMA 617

Metastatic castrate resistant prostate cancer

Open and accruing Jan 2021

Prof Emmett

ANZUP trials

Upfront PSMA Ph2

Docetaxel vs Docetaxel + LuPSMA 617

Newly diagnosed metastatic prostate cancer

Open and accruing Jan 2021

Prof Hofman

PROStic

LuPARP: ph1

Lu PSMA +olaparib

Metastatic castrate resistant prostate cancer

Closed but ongoing Jan 2021

Dr Shahneen Sandhu

PMCC

PRINCE: Ph

Lu PSMA + immuno

Metastatic castrate resistant prostate cancer

Closed but ongoing Jan 2021

Dr Shahneen Sandhu

PMCC

Our Funders

The department has been the recipient of multiple grant funds for these important investigator initiated trials in the last few years. These funders include:

Movember / Prostate cancer research alliance: ($4,000,000.00) awarded for the ENZA-p trial – now open and accruing across Australia and run by ANZUP and then CTC NHMRC trial groups.

Cancer Institute NSW – $3,750,000 funding support for PRIMARY, LuPIN, and multiple other trials.

St Vincent’s Clinic Foundation - $400,000.00 for ENZAp and $40,000.00 for PRIMARY trial

St Vincent’s Curran Foundation - $100,000.00 for the PRIMARY trial.

The research papers generated from research performed within the Theranostic & Nuclear Medicine service are outlined below:-



← Back To Main Page